Citations

Clear

626 citation(s) found for "Mehta, SH".

Mortality After Magnetic Resonance Imaging of the Brain in Patients With Cardiovascular Implantable Devices
Padmanabhan, Deepak , Jondal, Mary Lou, Hodge, David O. , Mehta, Ramila A. , Acker, Nancy G., Dalzell, Connie, Asirvatham, Samuel J. , Cha, Yong‐Mei , Felmlee, Joel P. , Watson, Robert E. , Friedman, Paul A. , Jondal, Mary L, Dalzell, Connie M, Kapa, Suraj , Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | January 10, 2018 | Volume: 11 | Issue: 1 | Pages: No page available

10.1161/circep.117.005480 | PMID 29321191 Get It

Background: Use of magnetic resonance imaging (MRI) brain is restricted in patients with cardiovascular implantable electronic devices (CIEDs). We proposed to determine whether mortality difference exists for patients with non–MRI-conditional CIEDs undergoing brain MRI compared with controls. Methods and Results: Retrospective analysis of prospectively collected data was performed to compare all-cause mortality in patients with CIEDs undergoing brain MRI (CIED-MRI) with 3 control groups matched for age, sex, imaging year, and type of CIED: (1) no CIED, brain MRI (no–CIED-MRI); (2) CIED, brain computerized tomography (CT) scan (CIED-CT); and (3) no CIED, brain CT (no–CIED-CT). The primary outcome was a significant difference ( P <0.05) between estimated mortality rates. Secondary outcomes were changes in device function before and after brain MRI. The estimated all-cause mortality at 5 years for the CIED-MRI group [mean age (±SD), 68.2 years (15.3 years); 61.2% men] was not significantly different from patients who underwent CT with or without a device (CIED-CT group: hazard ratio, 0.814; 95% confidence interval, 0.593–1.117; P =0.2; no–CIED-CT group: hazard ratio, 1.149; 95% confidence interval, 0.818–1.613; P =0.4). There was a significant increase in mortality between CIED-MRI and no–CIED-MRI groups (hazard ratio, 1.463; 95% confidence interval, 1.019–2.099; P =0.04). Conclusions: Brain MRI in patients with CIEDs does not carry an increased mortality risk compared with brain CT and can be performed with adherence to appropriate procedural protocols.
From a Silver Lining to the Silver Anniversary
Ashton, Rendell W. , Prakash, Udaya B. S., Mehta, Atul C.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | December 19, 2017 | Volume: 25 | Issue: 1 | Pages: 1-2

10.1097/lbr.0000000000000477 | PMID 29261573 Get It

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Chinnaiyan, Prakash , Won, Minhee , Wen, Patrick Y. , Rojiani, Amyn M. , Werner‐Wasik, Maria, Shih, Helen A. , Ashby, Lynn S., Yu, Hsiang-Hsuan Michael, Stieber, Volker W. , Malone, Shawn , Fiveash, John B. , Mohile, Nimish, Ahluwalia, Manmeet S. , Wendland, Merideth M, Stella, Philip J., Kee, Andrew Y., Tsai, Ya-Yu , Shih, Helen A , Wen, Patrick Yung , Mehta, Minesh P. , Ahluwalia, Manmeet S

Mayo Clinic

Neuro-Oncology | October 30, 2017 | Volume: 20 | Issue: 5 | Pages: 666-673

10.1093/neuonc/nox209 | PMID 29126203 Get It

Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke)
Froehler, Michael T. , Zaidat, Osama O., Aziz‐Sultan, Mohammad Ali , Klucznik, Richard , Hellinger, Frank R, Yavagal, Dileep R. , Yao, Tom L., Liebeskind, David S, Jadhav, Ashutosh P. , Gupta, Rishi , Hassan, Ameer E , Martin, Coleman, Bozorgchami, Hormozd, Kaushal, Ritesh , Gandhi, Ravi H. , Peterson, Eric C. , Given, Curtis A., Mehta, Brijesh , Deshmukh, Vivek R., Starkman, Sidney , Linfante, Italo , McPherson, Scott H., Kvamme, Peter , Grobelny, Thomas, Hussain, Muhammad Shazam , Thacker, Ike, Vora, Nirav , Monteith, Stephen J., Ecker, Robert D., Schirmer, Clemens M. , Sauvageau, Eric , Abou‐Chebl, Alex, Derdeyn, Colin P. , Maidan, Lucian, Badruddin, Aamir , Siddiqui, Adnan H. , Dumont, Travis M., Alhajeri, Abdulnasser, Taqi, Muhammad , Asi, Khaled, Carpenter, Jeffrey , Boulos, Alan S. , Jindal, Gaurav , Puri, Ajit S , Robinson, David , Kallmes, David F. , Baxter, Blaise, Jumaa, Mouhammad , Sunenshine, Peter, Majjhoo, Aniel, English, Joey , Fessler, Richard D., Martin, Jerry C., Mueller‐Kronast, Nils , Liebeskind, David S. , Liebeskind, David S. , Siddiqui, Adnan H , Hassan, Ameer E , Schirmer, Clemens M , Saver, Jeffrey L. , Jahan, Reza , Haussen, Diogo C , Nogueira, Raul G. , Dashti, Shervin R , Chen, Peng R , Chitale, Rohan V , Deshaies, Eric Michael , Suzuki, Shuichi , Almandoz, Josser E Delgado , Jadhav, Ashutosh P , Derdeyn, Colin P

Mayo Clinic

Circulation | September 25, 2017 | Volume: 136 | Issue: 24 | Pages: 2311-2321

10.1161/circulationaha.117.028920 | PMID 28943516 Get It

Background: Endovascular treatment with mechanical thrombectomy (MT) is beneficial for patients with acute stroke suffering a large-vessel occlusion, although treatment efficacy is highly time-dependent. We hypothesized that interhospital transfer to endovascular-capable centers would result in treatment delays and worse clinical outcomes compared with direct presentation. Methods: STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter, observational, single-arm study of real-world MT for acute stroke because of anterior-circulation large-vessel occlusion performed at 55 sites over 2 years, including 1000 patients with severe stroke and treated within 8 hours. Patients underwent MT with or without intravenous tissue plasminogen activator and were admitted to endovascular-capable centers via either interhospital transfer or direct presentation. The primary clinical outcome was functional independence (modified Rankin Score 0–2) at 90 days. We assessed (1) real-world time metrics of stroke care delivery, (2) outcome differences between direct and transfer patients undergoing MT, and (3) the potential impact of local hospital bypass. Results: A total of 984 patients were analyzed. Median onset-to-revascularization time was 202.0 minutes for direct versus 311.5 minutes for transfer patients ( P <0.001). Clinical outcomes were better in the direct group, with 60.0% (299/498) achieving functional independence compared with 52.2% (213/408) in the transfer group (odds ratio, 1.38; 95% confidence interval, 1.06–1.79; P =0.02). Likewise, excellent outcome (modified Rankin Score 0–1) was achieved in 47.4% (236/498) of direct patients versus 38.0% (155/408) of transfer patients (odds ratio, 1.47; 95% confidence interval, 1.13–1.92; P =0.005). Mortality did not differ between the 2 groups (15.1% for direct, 13.7% for transfer; P =0.55). Intravenous tissue plasminogen activator did not impact outcomes. Hypothetical bypass modeling for all transferred patients suggested that intravenous tissue plasminogen activator would be delayed by 12 minutes, but MT would be performed 91 minutes sooner if patients were routed directly to endovascular-capable centers. If bypass is limited to a 20-mile radius from onset, then intravenous tissue plasminogen activator would be delayed by 7 minutes and MT performed 94 minutes earlier. Conclusions: In this large, real-world study, interhospital transfer was associated with significant treatment delays and lower chance of good outcome. Strategies to facilitate more rapid identification of large-vessel occlusion and direct routing to endovascular-capable centers for patients with severe stroke may improve outcomes. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02239640.
Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype
Gerkin, Richard C. , Hentz, Joseph G. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caviness, John N., Dugger, Brittany N. , Belden, Christine M. , Smith, Brian H. , Sue, Lucia I., Davis, Kathryn, Zamrini, Edward , Beach, Thomas G. , Driver-Dunckley, Erika, Adler, Charles H. , Sabbagh, Marwan Noel , Serrano, Geidy E. , Dugger, Brittany N

Mayo Clinic

Annals of Clinical and Translational Neurology | September 8, 2017 | Volume: 4 | Issue: 10 | Pages: 714-721

10.1002/acn3.447 | PMID 29046880 Get It

AbstractObjectiveTo assess the predictive potential of the complete response pattern from the University of Pennsylvania Smell Identification Test for the diagnosis of Parkinson's disease.MethodsWe analyzed a large dataset from the Arizona Study of Aging and Neurodegenerative Disorders, a longitudinal clinicopathological study of health and disease in elderly volunteers. Using the complete pattern of responses to all 40 items in each subject's test, we built predictive models of neurodegenerative disease, and we validated these models out of sample by comparing model predictions against postmortem pathological diagnosis.ResultsConsistent with anatomical considerations, we found that the specific test response pattern had additional predictive power compared with a conventional measure – total test score – in Parkinson's disease, but not Alzheimer's disease. We also identified specific test questions that carry the greatest predictive power for disease diagnosis.InterpretationOlfactory ability has typically been assessed with either self‐report or total score on a multiple choice test. We showed that a more accurate clinical diagnosis can be made using the pattern of responses to all the test questions, and validated this against the “gold standard” of pathological diagnosis. Information in the response pattern also suggests specific modifications to the standard test that may optimize predictive power under the typical clinical constraint of limited time. We recommend that future studies retain the individual item responses for each subject, and not just the total score, both to enable more accurate diagnosis and to enable additional future insights.
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma
Burri, Stuart H., Gondi, Vinai , Brown, Paul D. , Mehta, Minesh P.

Mayo Clinic

American Journal of Clinical Oncology | August 23, 2017 | Volume: 41 | Issue: 2 | Pages: 191-196

10.1097/coc.0000000000000395 | PMID 28832384 Get It

Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival (OS). Various salvage chemotherapy strategies have been applied with limited success. Tumor Treating Fields (TTFields) are a novel treatment modality approved for treatment of either newly diagnosed or recurrent GBM. TTFields therapy involves a medical device and transducer arrays to provide targeted delivery of low intensity, intermediate frequency, alternating electric fields to produce antimitotic effects selective for rapidly dividing tumor cells with limited toxicity. In the phase 3 EF-14 trial, TTFields plus temozolomide provided significantly longer progression-free survival and OS compared with temozolomide alone in patients with newly diagnosed GBM after initial chemoradiotherapy. The addition of TTFields to standard therapy improved median OS from 15.6 to 20.5 months (P=0.04). In the phase 3 EF-11 trial, for recurrent GBM, TTFields provided comparable efficacy as investigator’s choice systemic therapy, with improved patient-reported quality of life and a lower incidence of serious adverse events. Primary toxicity associated with TTFields is skin irritation generally managed with array relocation and topical treatments including antibiotics and steroids. TTFields therapy has demonstrated proven efficacy in management of GBM, including improvement in OS for patients with newly diagnosed GBM, and is under current investigation in other brain and extracranial tumors.
Abstract CT161: METIS: A phase 3 study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC
Mehta, M.P., Gondi, Vinai , Brown, Paul D.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: CT161-CT161

10.1158/1538-7445.am2017-ct161 Get It

Abstract BACKGROUND Tumor Treating Fields (TTFields) are noninvasive regional antimitotic treatment modality, based on low intensity alternating electric fields. Efficacy of TTFields in non-small cell lung cancer (NSCLC) has been demonstrated in multiple in vitro and in vivo models, and in a phase I/II clinical study. TTFields treatment to the brain was shown to be safe and to extend overall survival in newly diagnosed glioblastoma patients. TRIAL DESIGN 270 patients with 1-10 brain metastases (BM) from NSCLC will be randomized in a ratio of 1:1 to receive stereotactic radio surgery (SRS) followed by either TTFields or supportive care alone. Patients are followed-up every two months until 2nd cerebral progression. Patients in the control arm may cross over to receive TTFields at the time of 2st cerebral progression. Objectives: To test the efficacy, safety and neurocognitive outcomes of TTFields in this patient population. Endpoints: Time to 1st cerebral progression based on the RANO-BM Criteria or neurological death (primary); time to neurocognitive failure based on the following tests: HVLT, COWAT and TMT; overall survival; radiological response rate; quality of life; adverse events severity and frequency (secondary). Main eligibility criteria: Karnofsky performance status (KPS) of 70 or above, 1 inoperable or 2-10 brain lesions amenable to SRS, optimal standard therapy for the extracranial disease, no brain-directed therapy, no signs of significantly increased intracranial pressure, no electronic implantable devices in the brain. Treatment: Continuous TTFields at 150 kHz for at least 18 hours per day will be applied to the brain within 7 days of SRS. The treatment system is a portable medical device allowing normal daily activities. The device delivers TTFields to the brain using 4 Transducer Arrays, which may be covered by a wig or a hat for cosmetic reasons. Patients will receive the best standard of care for their systemic disease. Statistical Considerations: This is a prospective, randomized, multicenter study for 270 patients. The sample size was calculated using a log-rank test (based on Lakatos 1988 and 2002) and has 80% power at a two sided alpha of 0.05 to detect a hazard ratio of 0.57. Citation Format: Minish P. Mehta, Vinai Gondi, Paul D. Brown. METIS: A phase 3 study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT161. doi:10.1158/1538-7445.AM2017-CT161
Essential Tremor and Depression
Aslam, Sana , Zhang, Nan , Caviness, John N., Driver‐Dunckley, Erika , Mehta, Shyamal H. , Belden, Christine M. , Zamrini, Edward , Beach, Thomas G. , Shill, Holly A. , Driver-Dunckley, Erika, Adler, Charles H. , Sabbagh, Marwan Noel

Mayo Clinic

Movement Disorders Clinical Practice | July 18, 2017 | Volume: 4 | Issue: 6 | Pages: 838-842

10.1002/mdc3.12530 | PMID 29805986 Get It

AbstractIntroductionDepression and neuropsychiatric disorders in individuals with essential tremor (ET) are not well characterized in the literature.MethodsWe compared 104 ET subjects with 481 non‐ET controls involved in the Arizona Study of Aging and Neurodegenerative Disorders. An analysis of baseline depression scales and neuropsychiatric inventory (NPI) was done between the two groups. Additionally, comparisons were made within the ET group based on tremor severity, duration of tremor, and age of onset.ResultsThere were no significant differences between the ET and non‐ET groups. There were no significant differences in the ET group above and below the median tremor duration. Additionally, no differences were found in the ET group based on objective measures of tremor severity, age of onset, or those with subjectively distressing tremor compared with those without.ConclusionThere were no significant differences in depressive symptoms between ET and non‐ET groups. Furthermore, no correlation was found between depressive symptoms in ET groups based on tremor severity, duration, or age of onset.
A Consensus Set of Outcomes for Parkinson’s Disease from the International Consortium for Health Outcomes Measurement
Roos, Paul de , Bloem, Bastiaan R. , Kelley, Thomas A., Antonini, Angelo , Dodel, Richard , Hagell, Peter , Mehta, Shyamal H. , Odin, Per , Chaudhuri, К. Ray , Wilson, Bil, Uitti, Ryan J. , Marras, Connie , Martínez‐Martín, Pablo , Weintraub, Daniel , Wilson, Bil, Antonini, Angelo

Mayo Clinic

Journal of Parkinson's Disease | June 30, 2017 | Volume: 7 | Issue: 3 | Pages: 533-543

10.3233/jpd-161055 | PMID 28671140 Get It

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL NON‐HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T‐CELL CONSORTIUM
Lunning, M., Mehta–Shah, Neha , Moskowitz, Alison J. , Beaven, Anne , Haverkos, Bradley M. , Lechowicz, MaryJo, Oki, Yasuhiro , Ansell, Stephen M. , Lunning, Matthew A. , Horwitz, Steven M. , Advani, Ranjana H. , Zain, Jasmine

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 411-412

10.1002/hon.2439_190 Get It